AR095036A1 - Compuestos analgésicos bicíclicos - Google Patents

Compuestos analgésicos bicíclicos

Info

Publication number
AR095036A1
AR095036A1 ARP140100734A ARP140100734A AR095036A1 AR 095036 A1 AR095036 A1 AR 095036A1 AR P140100734 A ARP140100734 A AR P140100734A AR P140100734 A ARP140100734 A AR P140100734A AR 095036 A1 AR095036 A1 AR 095036A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
compounds
compound
Prior art date
Application number
ARP140100734A
Other languages
English (en)
Spanish (es)
Inventor
Duane Bunker Kevin
Original Assignee
Kalyra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalyra Pharmaceuticals Inc filed Critical Kalyra Pharmaceuticals Inc
Publication of AR095036A1 publication Critical patent/AR095036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/41—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP140100734A 2013-03-14 2014-03-06 Compuestos analgésicos bicíclicos AR095036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361781580P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095036A1 true AR095036A1 (es) 2015-09-16

Family

ID=51530018

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100734A AR095036A1 (es) 2013-03-14 2014-03-06 Compuestos analgésicos bicíclicos

Country Status (8)

Country Link
US (6) US9447026B2 (enExample)
EP (1) EP2970104B1 (enExample)
JP (1) JP6506248B2 (enExample)
KR (1) KR102243637B1 (enExample)
AR (1) AR095036A1 (enExample)
CA (1) CA2903431C (enExample)
TW (1) TWI630194B (enExample)
WO (1) WO2014149819A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970104B1 (en) * 2013-03-14 2019-04-24 Zeno Royalties & Milestones, LLC Bicyclic analgesic compounds
CN108947867A (zh) * 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
CN113336653A (zh) 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
EP3193855B1 (en) * 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclic compounds
PL3277690T3 (pl) * 2015-04-03 2020-08-24 Recurium Ip Holdings, Llc Związki spirocykliczne
WO2017160926A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
CA3037064A1 (en) 2016-10-05 2018-04-12 Zeno Royalties & Milestones, LLC Spirocyclic compounds
US11242327B2 (en) * 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
EP3676297B1 (en) 2017-09-01 2023-05-17 Denali Therapeutics Inc. Compounds, compositions and methods
EP3781142A4 (en) 2018-04-19 2022-03-30 Merck Sharp & Dohme Corp. NEW [1.1.1] BICYCLO COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
BR112021015639A2 (pt) 2019-02-13 2021-10-05 Denali Therapeutics Inc. Compostos, composições e métodos
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL54795A (en) * 1978-05-26 1980-10-26 Yeda Res & Dev Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
WO1989012085A1 (en) 1988-06-03 1989-12-14 The University Of Texas System Compounds and methods based on [1.1.1]propellane
AU4743890A (en) 1988-12-06 1990-06-26 Upjohn Company, The Antibacterial quinolone compounds
AU626949B2 (en) 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
US5262417A (en) 1988-12-06 1993-11-16 The Upjohn Company Antibacterial quinolone compounds
SK13532000A3 (sk) 1998-03-17 2002-07-02 Pfizer Products Inc. Bicyklo [2.2.1] heptány a príbuzné zlúčeniny, farmaceutické kompozície a spôsoby liečenia na ich báze
AU3898000A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of neuropathic pain or fibromyalgia
DE10025946A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
CA2409927A1 (en) 2000-05-31 2001-12-06 Warner-Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
DE10164348A1 (de) 2001-12-28 2003-07-17 Basf Ag Verfahren zur Herstellung von 1-Methoypropanol-2
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
WO2006024018A2 (en) 2004-08-24 2006-03-02 Neuromolecular Pharmaceuticals, Inc. Compositions for treating nociceptive pain
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
JP2008120797A (ja) 2006-10-19 2008-05-29 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換フェニルアセトアミド誘導体からなる医薬
AU2007338412B2 (en) 2006-12-27 2013-03-14 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
WO2008096218A1 (en) 2007-02-06 2008-08-14 Pfizer Inc. 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer
CN104193741B (zh) 2007-10-01 2016-08-24 阿尔法梅根有限责任公司 作为α7-烟碱乙酰胆碱受体配体的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
CN102762534A (zh) 2009-09-18 2012-10-31 扎里卡斯药品有限公司 作为钙通道阻断剂的芳基砜衍生物
WO2012003231A1 (en) 2010-06-30 2012-01-05 Upsher-Smith Laboratories, Inc. Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
CN103442568A (zh) 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
CA2832291C (en) 2011-04-05 2015-12-01 Pfizer Limited Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
CN111471021B (zh) 2011-04-22 2024-04-02 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
EA022375B1 (ru) 2011-04-22 2015-12-30 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
TWI601727B (zh) 2011-08-12 2017-10-11 日產化學工業股份有限公司 三環雜環化合物及ｊａｋ（傑納斯激酶）抑制劑
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013126856A1 (en) 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2013161994A1 (ja) 2012-04-27 2013-10-31 日本臓器製薬株式会社 鎮痛剤
EP2970104B1 (en) 2013-03-14 2019-04-24 Zeno Royalties & Milestones, LLC Bicyclic analgesic compounds
US20160076098A1 (en) 2013-04-12 2016-03-17 Drexel University Methods of diagnosing and treating chronic pain
AU2014301295C1 (en) 2013-06-28 2018-03-15 Evotec International Gmbh Sulfoximine substituted quinazolines and their use as MNK1 and/or MNK2 kinase inhibitors
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015022263A1 (en) 2013-08-12 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
CA2926207C (en) 2013-10-21 2022-06-21 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
CN103588672A (zh) 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物
CN103588668A (zh) 2013-10-28 2014-02-19 史克勇 化合物
CN108947867A (zh) 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
AU2014369031A1 (en) 2013-12-20 2016-07-07 Signal Pharmaceuticals, Llc Substituted Diaminopyrimidyl Compounds, compositions thereof, and methods of treatment therewith
CN113336653A (zh) 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
CA2945128A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
EP3193855B1 (en) 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclic compounds
WO2017160926A1 (en) 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds

Also Published As

Publication number Publication date
JP6506248B2 (ja) 2019-04-24
CA2903431A1 (en) 2014-09-25
KR20150131240A (ko) 2015-11-24
US9447026B2 (en) 2016-09-20
US9693975B2 (en) 2017-07-04
EP2970104B1 (en) 2019-04-24
HK1219472A1 (en) 2017-04-07
WO2014149819A1 (en) 2014-09-25
US20140275245A1 (en) 2014-09-18
JP2016518317A (ja) 2016-06-23
US20160374968A1 (en) 2016-12-29
EP2970104A1 (en) 2016-01-20
US20160355462A1 (en) 2016-12-08
US9724316B2 (en) 2017-08-08
EP2970104A4 (en) 2016-11-16
US20180042871A1 (en) 2018-02-15
US9447025B2 (en) 2016-09-20
KR102243637B1 (ko) 2021-04-26
US20190298668A1 (en) 2019-10-03
TWI630194B (zh) 2018-07-21
US10251851B2 (en) 2019-04-09
TW201443001A (zh) 2014-11-16
CA2903431C (en) 2022-12-06
US20160016892A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
AR095036A1 (es) Compuestos analgésicos bicíclicos
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
AR102468A1 (es) Métodos para la preparación de ribósidos
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
PE20191710A1 (es) Modulador del receptor de androgeno y usos de este
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
AR102948A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
AR089768A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR091093A1 (es) Tienopirimidinas
AR099970A1 (es) Amidas, carbamatos y ureas que contienen carbazol como moduladores de criptocromo
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR094300A1 (es) Derivados de quinolonas
AR093937A1 (es) Compuestos quimicos
CR20150056A (es) Derivados de azaindol
JP2014218522A5 (enExample)
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2016017133A (es) Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70.

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure